SCHEMBL6345667

SCHEMBL6345667

O=C(c1ccccc1)c1coc2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.61
RAB9A P51151 3/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
MAOB P27338 2/20 0.59
MEN1 O00255 4/20 0.57
SIRT1 Q96EB6 2/20 0.54
ALDH1A1 P00352 4/20 0.53
LMNA P02545 3/20 0.53
HPGD P15428 2/20 0.53
MAPK1 P28482 2/20 0.53
PKM P14618 1/20 0.53
TSHR P16473 1/20 0.53
ATM Q13315 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ADORA2B P29275 1/20 0.50
NPC1 O15118 4/20 0.49
MAPT P10636 4/20 0.49
HTT P42858 3/20 0.49
CASP3 P42574 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8761733 0.88 MAOB (0.61) KMT2ARAB9AL3MBTL1SMN1; SMN2MAOB
SCHEMBL25567893 0.88 MAOB (0.73) KMT2ARAB9AL3MBTL1SMN1; SMN2MAOB
SCHEMBL9594944 0.88 NPC1 (0.60) KMT2ARAB9AL3MBTL1SMN1; SMN2MAOB
SCHEMBL11856874 0.86 KMT2A (0.50) KMT2ARAB9AL3MBTL1SMN1; SMN2MAOB
SCHEMBL588963 0.82 KMT2A (0.71) KMT2ARAB9AL3MBTL1SMN1; SMN2MAOB
SCHEMBL70456 0.82 MAOB (0.76) RAB9AMAOBALDH1A1HPGDHSD17B10
SCHEMBL289145 0.82 SIRT1 (0.81) KMT2ARAB9AL3MBTL1SMN1; SMN2MAOB
SCHEMBL27822584 0.81 MAOB (0.73) RAB9AMAOBALDH1A1HPGDHSD17B10
Hydrochloric Acid SCHEMBL87683 0.81 MAOB (0.73) RAB9AMAOBALDH1A1HPGDHSD17B10
SCHEMBL13655497 0.81 MAOB (0.62) RAB9AMAOBHPGDHSD17B10ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102370632-A Application of SIRT1 micro-molecular inhibitor in preparation of medicines for treating or preventing caner and protein deacetylation related diseases SHANGHAI INST MATERIA MEDICA 2012-03-14 CN claimed
EP-0425359-B1 Process for the preparation of 3-benzoyl-benzofuran derivatives SANOFI SA (FR) 1995-10-11 EP claimed
US-5266711-A Process for the preparation of 3-benzoyl benzofuran derivatives SANOFI (FR) 1993-11-30 US claimed
CN-108484546-B A kind of preparation method of 2- methyl -3- benzoyl benzofuran derivatives 江南大学 2019-11-08 CN disclosed
CN-108484546-A A kind of preparation method of 2- methyl -3- benzoyl benzofuran derivatives 江南大学 2018-09-04 CN disclosed
US-9890132-B2 Process for the preparation of anti-inflammatory aroylbenzofuran compounds COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-02-13 US disclosed
US-9890132-B2 Process for the preparation of anti-inflammatory aroylbenzofuran compounds COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2018-02-13 US disclosed
US-20160229827-A1 A PROCESS FOR THE PREPARATION OF ANTI-INFLAMMATORY AROYLBENZOFURAN COMPOUNDS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-08-11 US disclosed
CN-102370632-A Application of SIRT1 micro-molecular inhibitor in preparation of medicines for treating or preventing caner and protein deacetylation related diseases SHANGHAI INST MATERIA MEDICA 2012-03-14 CN disclosed
US-6844358-B2 Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2005-01-18 US disclosed
US-20040102480-A1 Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2004-05-27 US disclosed
WO-1999058519-A1 PHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed
US-5854282-A 3-benzoyl benzofuran derivatives as thyroid hormone antagonists KARO BIO AB (SE) 1998-12-29 US disclosed
EP-0425359-B1 Process for the preparation of 3-benzoyl-benzofuran derivatives SANOFI SA (FR) 1995-10-11 EP disclosed
US-5266711-A Process for the preparation of 3-benzoyl benzofuran derivatives SANOFI (FR) 1993-11-30 US disclosed
US-5266711-A Process for the preparation of 3-benzoyl benzofuran derivatives SANOFI (FR) 1993-11-30 US disclosed
US-5266711-A Process for the preparation of 3-benzoyl benzofuran derivatives SANOFI (FR) 1993-11-30 US disclosed
EP-0425359-A1 Process for the preparation of 3-benzoyl-benzofuran derivatives SANOFI (FR) 1991-05-02 EP disclosed
EP-0425359-A1 Process for the preparation of 3-benzoyl-benzofuran derivatives SANOFI (FR) 1991-05-02 EP disclosed
US-4766223-A FROM ALKYL BENZOFURAN AND 4-METHOXYBENZOYL HALIDE; HYDROLYSIS, DEMETHYLATION SANOFI (FR) 1988-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229827-A1 A PROCESS FOR THE PREPARATION OF ANTI-INFLAMMATORY AROYLBENZOFURAN COMPOUNDS LITAF, IL1B, CYP2F1 KMT2A 4215/4885RAB9A 4111/4885L3MBTL1 4485/4885
US-20040102480-A1 Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, GCKR KMT2A 4051/4885RAB9A 2395/4885L3MBTL1 2169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.